Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phio Pharmaceuticals Corp. (NASDAQ: PHIO) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phio is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology in immuno-oncology, with a lead program, PH-762, targeting the PD-1 gene in skin cancers.
Through this page, you can review current and historical Forms 8-K in which Phio reports material events. Recent 8-K filings describe clinical milestones for the Phase 1b trial of PH-762 (NCT 06014086), such as completion of enrollment, interim pathology results, and Safety Monitoring Committee findings that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed at reported dose levels. Other 8-Ks detail warrant inducement agreements, gross proceeds from warrant exercises, and the terms of new warrants and placement agent warrants.
Phio’s proxy materials, including its Definitive Proxy Statement on Schedule DEF 14A, outline governance and compensation matters. These filings cover the election of directors, ratification of the independent registered public accounting firm, amendments to the 2020 Long Term Incentive Plan to increase share availability, and advisory votes on executive compensation and the frequency of such votes. They also describe the conduct of the annual meeting and voting results on each proposal.
As Phio advances its INTASYL platform and PH-762 program, investors can use this filings page to monitor financial reporting, capital structure changes, and corporate actions. Stock Titan enhances these documents with AI-powered summaries that highlight key points in complex filings, helping readers quickly identify items such as clinical development updates, financing terms, and board decisions without manually parsing every section.
In addition, the filings page links to disclosures about nonclinical protocol acceptance by the FDA, agreements for cGMP manufacturing of PH-762, and other events that influence the company’s development and financing strategy. For those analyzing PHIO, this centralized view of 8-Ks, proxy statements, and related filings offers a concise way to follow the regulatory record that underpins Phio’s public communications.
Phio Pharmaceuticals director Patricia A. Bradford received 18,500 shares of common stock underlying a restricted stock unit award on February 5, 2026. These shares will vest on the first anniversary of the grant. After this award, she beneficially owns 45,651 common shares directly, including unvested restricted stock units, with amounts adjusted for prior reverse stock splits.
Phio Pharmaceuticals’ Chairman, President and CEO Robert J. Bitterman received 120,000 shares of common stock on February 5, 2026 through a restricted stock unit (RSU) grant. The Form 4 shows the shares were acquired at a price of $0 per share, reflecting an equity award rather than an open‑market purchase.
The 120,000 shares represent RSUs that will vest on the first anniversary of the grant. After this award, Bitterman beneficially owns 411,421 shares of Phio common stock in direct ownership, which includes shares underlying unvested RSUs.
PHIO Pharmaceuticals Corp. reported new clinical results from its intratumoral PH-762 dose-escalation trial in cutaneous carcinoma. The company highlighted that safety and tolerability were favorable across all dose levels. Pathology data showed a 70% overall response rate for squamous cell carcinomas, and among the 14 responders, 10 achieved 100% clearance of their tumors. These findings suggest PH-762 demonstrated meaningful anti-tumor activity in this early study while maintaining a manageable safety profile.
Phio Pharmaceuticals Corp. reported a development milestone for its investigational therapy PH-762. On December 23, 2025, the company announced that the U.S. Food and Drug Administration accepted its nonclinical protocol study design for PH-762, a key step that allows planned toxicology testing to move ahead. The company stated that this toxicology study is expected to begin in the first quarter of 2026, marking progress in advancing PH-762 through the preclinical development process.
PHIO Pharmaceuticals Corp. reported that it has completed enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of its INTASYL siRNA lead compound, PH-762. This means all planned participants have been enrolled and the study can now proceed using the full patient group for evaluation. The update was shared through a press release dated November 25, 2025, which is included as an exhibit to this report.
Phio Pharmaceuticals Corp. (PHIO) reported an insider stock purchase by its Chairman, President and CEO, who is also a director. On 11/21/2025, the executive bought 5,000 shares of common stock at a price of $1.14 per share in an open-market transaction coded as a purchase.
After this transaction, the executive beneficially owns 281,421 shares of Phio common stock, which includes shares underlying unvested restricted stock units. The filing was made as a Form 4 by a single reporting person, indicating a change in that individual’s ownership position in the company.
Phio Pharmaceuticals Corp. has filed a resale registration statement covering up to 11,763,800 shares of common stock issuable upon the exercise of outstanding warrants. These shares will be sold from time to time by existing selling stockholders, and the company itself is not selling any shares under this prospectus. Phio will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised, which at full cash exercise would total approximately $24.5 million. The company has already raised about $13.4 million from recent warrant exercises tied to November 2025 inducement agreements. Any future warrant exercise proceeds are expected to support working capital and development of PH-762 for cutaneous carcinomas following encouraging Phase 1b safety and pathology results.
Phio Pharmaceuticals Corp. (PHIO) reported an insider purchase by its Chairman, President and CEO. On 11/18/2025, the executive, who also serves as a director, bought 5,000 shares of Phio common stock at a price of $1.27 per share in an open-market transaction coded "P" for purchase.
After this transaction, the reporting person beneficially owned 276,421 shares of common stock, which includes shares underlying unvested restricted stock units. All reported holdings are listed as directly owned.
Phio Pharmaceuticals (PHIO) reported Q3 2025 results showing a net loss of $2.392 million on operating expenses of $2.505 million. Cash and cash equivalents were $10.705 million as of September 30, 2025, up from $5.382 million at year-end 2024, reflecting warrant exercises and registered direct offerings.
Subsequent to quarter-end, Phio entered inducement agreements that generated approximately $13.4 million in gross proceeds, with anticipated fees of $1.3 million, and issued new Series A warrants. The company states it believes it has sufficient liquidity for at least 12 months with these proceeds. Shares outstanding were 5,784,770 at September 30, 2025, and 10,764,428 as of November 11, 2025.
R&D expense was $1.181 million in Q3, driven by PH-762 clinical and CMC activity; G&A was $1.324 million. Year-to-date net loss was $6.327 million. In its ongoing Phase 1b trial of intratumoral PH-762, the fifth cohort showed 100% tumor clearance in one patient, >90% in a second, and >50% in a third at Day 36; no dose-limiting toxicities have been observed to date.
Phio Pharmaceuticals Corp. filed an 8-K announcing it reported financial results for the quarter ended September 30, 2025. The company furnished a related press release as Exhibit 99.1.
The disclosure under Item 2.02 is furnished, not filed, and will only be incorporated by reference into other filings if expressly stated. PHIO’s common stock trades on The Nasdaq Capital Market.